Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma

Press/Media: Press / Media

PeriodNov 19 2020

Media coverage

10

Media coverage

  • TitlePositive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletMarket News Publishing
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletIndia Pharma News
    CountryIndia
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletYahoo! Finance
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletMarketScreener.com
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletJotup
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletBioSpace
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletBiotechgate
    CountrySwitzerland
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT„¢ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletGlobeNewswire
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner
  • TitlePlus Therapeutics Announces Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma
    Media name/outletNewbridge Securities Corporation
    CountryUnited States
    Date11/19/20
    PersonsAndrew Brenner